Poly(ADP-ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability. Olaparib, the first-in-class PARP inhibitor, has shown remarkable clinical benefits in the treatment of BRCA-mutated ovarian or breast cancer. However, the undesirable hematological toxicity and phar- 
| INTRODUC TI ON
The family of PARPs is characterized by the ability to catalyze the addition of PAR to their target proteins. 1 Poly (ADP-ribose) polymerase 1, which accounts for 80% of cellular PARP activity, functions as a DNA repair factor in various DNA repairing processes. 1 Mechanically, PARP1 is recruited to DNA damage sites and catalyzes PAR synthesis, leading to increased redistribution of PARP1 on activated genes, modulation of the chromatin structure, and recruitment of the DNA repair machinery. 2 In addition, PARP1 plays a role in cellular processes such as transcriptional regulation, telomere cohesion, and mitotic spindle formation. 3 Poly(ADP-ribose) polymerase inhibitors show effective singleagent activity against cancers harboring HR defects. BRCA1/2 defects are the most extensively studied indication involved in HR in regards to PARP inhibition. A cell that is BRCA-deficient has reduced capacity to repair DNA DSBs by HR and is consequently hypersensitive to PARP inhibitors through the concept of synthetic lethality. 4, 5 The finding that PARP inhibition is exquisitely effective against BRCA-deficient cancers greatly boosts the development of PARP inhibitors as anticancer agents. 6 Olaparib was the first PARP inhibitor to be introduced into the clinic for the treatment of BRCA-mutated ovarian cancer and is the first and only PARP inhibitor approved in BRCA-mutated, HER2-negative metastatic breast cancer. To date, 3
PARP inhibitors (olaparib, rucaparib, and niraparib) have been approved by the FDA.
Responses to PARP inhibitors among patients with BRCAmutated ovarian or breast cancer are sufficiently profound to support the approval of these agents, but treatment-related toxicities are common and restrict the clinical applications of PARP inhibitors. 7 Among the three approved PARP inhibitors, niraparib has the highest rate of thrombocytopenia; 14.7% of patients discontinued treatment due to toxicity and 68.9% required dose reductions in the ENGOT-OV16/NOVA trial. 8 Rucaparib has the highest rate of elevations in liver transaminases and 55% of patients required dose reductions in the ARIEL3 trial. 9 Olaparib shows a relatively safe profile:
apart from anemia, toxicities related to olaparib were low grade. 10 Nonetheless, the toxicity remains an issue of concern and 25% of patients required dose reductions in the SOLO2/ENGOT-Ov21 trial. 11 One of the major obstacles restricting the safety and efficacy of olaparib is its undesirable pharmacokinetic properties. Olaparib has a short half-life and the exposure of olaparib achieved in tumor
is only approximately 40% of that in plasma. 12 In the clinic, patients need to take 8 capsules twice a day (400 mg per dose) or 2 tablets twice a day (300 mg per dose) to ensure the efficacy of the drug.
Because of individual variations in drug metabolism, the high dosage of olaparib leads to high coefficient of variation of drug exposure and concentrations, 10 which results in severe toxicity in some patients. Therefore, further structural modification and optimization of olaparib to improve the pharmaceutical properties and toxicity profile is of significant clinical value.
In order to improve the efficacy and expand the indications of PARP inhibitors, great efforts have been made to explore the combination of PARP inhibitors with other therapeutic agents, such as alkylating agents (temozolomide), platinum agents, and taxanes. 13 However, in clinical trials, PARP inhibitors combined with temozolomide led to severe hematological toxicity, 14 and PARP inhibitors combined with paclitaxel had no significant improvement in the overall survival. 15 Therefore, more efforts are needed to explore optimal combination regimens.
We rationally designed and synthesized a series of deriva- 
| MATERIAL SANDME THODS

| ReagentsandAbs
Fluzoparib was provided by Jiangsu Hengrui Medicine Co. (Shanghai, China). Olaparib was purchased from Selleckchem (Houston, TX, USA). Antibodies against γH2AX, p-CDK1, cyclin B1, caspase 8, caspase 9, cleaved caspase 3, and β-tubulin were purchased from Cell
Signaling Technology (Beverly, MA, USA). Anti-RAD51 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-PAR Ab and PARP universal colorimetric assay kit were purchased from Trevigen (Gaithersburg, MD, USA).
| Cellculture
V-C8 and V-C8#13-5 cell lines were kindly provided by Professor M. Zdzienicka (Leiden University, Amsterdam, the Netherlands).
UWB1.289, UWB1.289+BRCA1, MDA-MB-436, MX-1, SW620,
and NCI-N87 cell lines were purchased from ATCC (Manassas, VA, USA). The OVCAR-8 cell line was purchased from the NCIFrederick Cancer DCTD Tumor Repository (Frederick, MD, USA).
Cells were cultured according to instructions provided by the manufacturers.
| Enzymeactivity
The inhibition on PARP1 enzymatic activity was determined by ELISA according to the manufacturer's instructions. A 450 was measured using 
| Moleculardocking
The PARP1 structure from a crystal of PARP1/olaparib complex 16 was used as the template structure. The X-ray crystal structure of this PARP1/olaparib complex was obtained from the Protein Data Bank (PDB code: 5DS3). Glide, LigPrep, Maestro and PyMOL were obtained from Schrödinger (New York, NY, USA). Molecular docking was carried out using Glide version 6.9 in its SP mode. LigPrep version 3.6 was applied to preprocess the compound using default parameters. The obtained docked poses were analyzed with Maestro, PyMOL, and LigPlot (European Bioinformatics Institute, Hinxton, Cambridgeshire, UK).
| Cellproliferationassay
Cells were treated with PARP inhibitors alone or in combination with the indicated anticancer drugs for 3 days (V-C8, V-C8#13-5,
UWB1
.289, and UWB1.289+BRCA1) or 5 days (all the other cells).
The IC 50 values were determined by sulforhodamine B assay as described previously. 17 
| Westernblotanalysis
The standard western blotting 17 was used to detect the changes in protein levels caused by the indicated treatments.
| Cellcycleanalysis
Cells were fixed in ethanol and stained with propidium iodide following standard methods. The cell cycle was analyzed by FACS using a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA).
| Animalstudies
| Pharmacokinetic/pharmacodynamicstudies in mice
Female Balb/cA nude mice (5-6 weeks old) were purchased from Shanghai Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). Studies were carried out as described previously. 16 Tumor samples were lysed with RIPA buffer and analyzed by western blotting. 
| Pharmacokineticstudiesinrats
| Acutetoxicityinmice
Mice (female, n = 6) received a single oral dose of fluzoparib at 1000 mg/kg. Individual body weight was measured for 21 days.
| Acuteandchronictoxicityinrats
In the acute toxicity study, SD rats (female, n = 6) received a single oral dose of fluzoparib at 2000 mg/kg and were observed for 14 days. In the chronic toxicity study, SD rats (female, n = 15) received fluzoparib at 30 mg/kg for the first 66 days, at 60 mg/kg for the next 24 days, and were then observed for another 28 days without treatment. Clinical signs and histopathology were examined in both studies. 
| Cell-line-derivedxenograftmodel
| Patient-derivedxenograftmodel
Animal studies using gastric model STO#069 were carried out by 
| Statisticalanalysis
Data were analyzed with GraphPad Prism software. Two-tailed Student's t tests were used to determine the statistical significance of differences between 2 groups.
| RE SULTS
| FluzoparibisapotentinhibitorofPARP1
We first examined the inhibitory activities of fluzoparib ( Figure 1A) in a cell-free enzymatic assay against PARP1. Fluzoparib significantly inhibited PARP1 activity, with an IC 50 value of 1.46 ± 0.72 nmol/L, which was close to that of olaparib (IC 50 , 1.34 ± 0.78 nmol/L) ( Figure 1B ). We then explored the binding sites of fluzoparib in PARP1 using structural modeling. As shown in Figure 1C , fluzoparib was well ordered in the catalytic active site of PARP1 with the same binding mode as olaparib. Together, these data indicate that fluzoparib is a potent PARP1 inhibitor.
| FluzoparibinducespersistentDSBsin HR-deficientcells
Unrepaired single-strand breaks induced by PARP1 inhibition will eventually be converted to DSBs, which can be normally repaired by HR. 18 We detected RAD51 foci, the indicator of HR repair, after treatment 
| FluzoparibinducesG 2 /Marrestandapoptosis inHR-deficientcells
DNA DSBs are supposed to evoke the G 2 /M checkpoint in cells, leading to G 2 /M phase arrest and eventual apoptosis. 19 We thus 
| Fluzoparibselectivelyinhibits proliferationofHR-deficientcancercellsand sensitizesbothHR-deficientandHR-proficientcancer cellstocytotoxicdrugs
We (Table 1) . Fluzoparib showed similar antiproliferative effects to olaparib in all these cells.
The combination of PARP inhibitor with cytotoxic drugs is a rational strategy in the clinic. We thus evaluated the antiproliferative effects of fluzoparib combined with TMZ, cisplatin, or paclitaxel.
As shown in Figure 3 Collectively, the data suggest that fluzoparib is a PARP inhibitor with potent in vitro anticancer activity.
| Pharmacokinetic/pharmacodynamic characteristicsoffluzoparib
We then assessed the pharmacokinetic profile of fluzoparib in MDA-MB-436 xenograft-bearing mice. After a single oral dose at 0.3, 1, or 3 mg/kg, fluzoparib was rapidly absorbed and rapidly cleared from blood at all dose levels; plasma concentrations of fluzoparib quickly reached maximum within 2 hours and were merely detected (<1.0 ng/mL) at 24 hours post dosing ( Figure 4A ).
In contrast, concentrations of fluzoparib in tumor remained at high levels even at 24 hours after dosing (57.9 ± 16.6, 39.3 ± 8.2, and 85.6 ± 102.0 ng/g for doses of 0.3, 1, and 3 mg/kg, respectively).
The exposure of fluzoparib increased over its dose escalation in both plasma and tumor. Notably, the exposure (AUC 0-24 hours ) of fluzoparib in tumor was 25.0, 14.6, and 6.7-fold higher than that in plasma for doses 0.3, 1, and 3 mg/kg, respectively. We further assessed the pharmacokinetic profile of fluzoparib in female rats.
After a single oral dose at 4 mg/kg, the exposure (AUC 0-24 hours ) of fluzoparib was 3293.1 μg·hour/L, which was higher than that of olaparib reported at 5 mg/kg (2380 μg·hour/L). 20 Moreover, the bioavailability of fluzoparib (35.8%) was also higher than that of olaparib (<20%). 
| Acuteandchronictoxicityoffluzoparib
The acute toxicity of fluzoparib was investigated in both mice and rats. A single oral dose of fluzoparib at either 1000 mg/kg in female mice or 2000 mg/kg in female rats caused no mortalities or adverse signs. All mice ( Figure 5A ) and rats ( Figure 5B) gained weight over the course of the study. The chronic toxicity of fluzoparib was also investigated. Female rats received daily oral treatment with fluzoparib at 30 mg/kg for the first 66 days, at 60 mg/kg for the following 24 days, and then were observed for another 28 days without treatment. There were no abnormal changes in clinical signs or body weights ( Figure 5C ) during the study. Thus, fluzoparib is a drug with a good toxicity profile.
| Invivoantitumoractivityoffluzoparibin cancercell-line-derivedxenograftmodels
The antitumor potential of fluzoparib was investigated in MDA-MB-436 (BRCA1-deficient) xenograft models in vivo. As shown in The better lipid solubility of fluzoparib might make it easier to enter xenografts. Olaparib has been shown to be excluded from the central nervous systems under normal conditions but reliably penetrated recurrent glioblastoma at therapeutic levels. 7 It was assumable that fluzoparib might be easier to cross the blood-brain barrier and have a potential advantage in the treatment of brain tumor. More importantly, the exposure and bioavailability of fluzoparib in female rats were both higher than those of olaparib. 20 All these data supported that fluzoparib was a drug with favorable pharmacokinetic/pharmacodynamic properties. Another significant characteristic of fluzoparib was its favorable toxicity profile. It has been reported that hematologic toxicities, including neutropenia, thrombocytopenia, and anemia are major adverse effects of PARP inhibitors and greatly limit their clinical application. 21 In an acute toxicity study of olaparib, a single oral dose at 300 mg/kg in female rats led to animal death on day 2
| D ISCUSS I ON
and produced abnormal clinical signs, such as salivation, lachrymation, hypothermia, hunched posture, and palpebral closure. 20 In this study,
we raised the dose of fluzoparib to 1000 mg/kg in female mice and 2000 mg/kg in female rats; even so, no mortality or adverse signs were found. In a chronic toxicity study of olaparib, continuous oral dosing at 40 mg/kg for 28 days in female rats caused weight-easing, hematologic toxicities (changes in white cell populations, red blood cell parameters, and the precursor hematopoietic cells in the bone marrow) and histopathological changes (bone marrow, spleen, liver, and thymus). 20 In this study, fluzoparib was given orally for a longer time Administration for the treatment of late-stage gastric cancer. 22 It is suggested that anti-angiogenic drugs act by blocking angiogenesis and, as a consequence, inducing hypoxia. 23 Chronic hypoxia can decrease the synthesis of BRCA1 24 and RAD51, 25 and thus decrease HR in cancer cells. 25 Several studies report that anti-angiogenic drugs can potentiate PARP inhibitors. 26 Here, we show that fluzoparib combined with apatinib shows robust antitumor activity.
F I G U R E 7
Antitumor activity of fluzoparib in patient-derived xenograft models. Nude mice bearing xenografts derived from gastric tumor of a patient were randomized into control (n = 6) or treatment (n = 6) groups. Control group was given vehicle and treatment groups were given fluzoparib (F, 30 mg/kg, p.o.), apatinib (A, 50 mg/kg, p.o.), cisplatin (C, 5 mg/kg, i.p.), and paclitaxel (P, 15 mg/kg, i.p.) alone or in combination. Top panel, dosing schedule; bottom panel, tumor volume and body weight. Error bars represent mean ± SEM Based on these data, a phase I study to evaluate the tolerability and efficacy of fluzoparib in combination with apatinib in recurrent ovarian cancer or triple negative breast cancer has been initiated (NCT03075462). In addition, we find that the 3-drug combination of fluzoparib, apatinib, and paclitaxel showed improved antitumor effects without increased toxicity. This is the first report to suggest that the combination of a PARP inhibitor with an anti-angiogenic drug can potentiate the efficacy of cytotoxic agents. Based on this finding, a phase I study to evaluate the tolerability and efficacy of fluzoparib in combination with apatinib and paclitaxel in recurrent and metastatic gastric cancer that progresses following first-line therapy has been initiated (NCT03026881).
Together, our study showed that fluzoparib, characterized as a novel PARP inhibitor, had potent antitumor activity in preclinical models. Fluzoparib potently inhibited PARP1 enzyme activity, induced persistent DSBs, G 2 /M arrest, and apoptosis in HR-deficient cells, selectively inhibited the proliferation of HR-deficient cells, and sensitized both HR-deficient and HR-proficient cells to cytotoxic drugs.
Fluzoparib showed good pharmacokinetic properties, favorable toxicity profile, and robust in vivo antitumor activity. In particular, fluzoparib in combination with apatinib, or in combination with paclitaxel plus apatinib, showed remarkable antitumor effects without increased toxicity. All these features supported its undergoing clinical trials. We thank Professor Jianguo Sun (China Pharmaceutical University)
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